Q32 Bio Inc.
- QTTB
- NASDAQ
- Biotechnology
- Autoimmune Disease Biologics
- Inflammation Therapeutics
- Clinical-Stage Biotech
$7.79
Today +3.59%Quote Oct 19, 2026, 08:00 PM UTC
−26.09%over the last month
Max drawdown −28.9%From 1-month high −26.3%3 months −49.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Q32 Bio
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
22
Founded
2017
Market value
$231.9M
Quote Oct 19
Floor
$6.82
12.5% below price
Resistance
$7.98
2.5% above price
Price vs analyst targets
8 analysts
Lowest target
$14.00Highest target
$66.00
$14.00Highest target
$66.00
- Price $7.79
- Average target $36.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 369% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about QTTBPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free